| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2025 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202-1237 | COOK | USA | R41DK142544 | AGT001 for Delayed Graft Function in Kidney Transplantation | 000 | 1 | NIH | 8/20/2026 | $0 |
| | 2026 | 2025 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202 | COOK | USA | R43DK143839 | AGT001 for Scleroderma Kidney | 001 | 1 | NIH | 8/21/2026 | $0 |
| | 2026 | 2025 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202 | COOK | USA | R43DK143839 | AGT001 for Scleroderma Kidney | 000 | 1 | NIH | 12/8/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $610,099 ) |
| | 2025 | 2025 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202-1237 | COOK | USA | R41DK142544 | AGT001 for Delayed Graft Function in Kidney Transplantation | 000 | 1 | NIH | 9/4/2025 | $314,355 |
| | 2025 | 2025 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202 | COOK | USA | R43DK143839 | AGT001 for Scleroderma Kidney | 000 | 1 | NIH | 9/15/2025 | $295,744 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202-1237 | COOK | USA | R43HL160432 | Lung delivery of novel ACE2 variants for COVID-19 | 000 | 1 | NIH | 7/12/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202-1237 | COOK | USA | R43HL160432 | Lung delivery of novel ACE2 variants for COVID-19 | 000 | 1 | NIH | 11/18/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $299,842 ) |
| | 2022 | 2022 | ANGIOTENSIN THERAPEUTICS INC | 1001 MAPLE AVE | EVANSTON | IL | 60202-1237 | COOK | USA | R43HL160432 | Lung delivery of novel ACE2 variants for COVID-19 | 000 | 1 | NIH | 8/16/2022 | $299,842 |
|
|
